Angeles Wealth Management LLC Reduces Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Angeles Wealth Management LLC trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,498 shares of the medical research company’s stock after selling 102 shares during the quarter. Angeles Wealth Management LLC’s holdings in IQVIA were worth $294,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA in the third quarter worth about $27,000. Synergy Asset Management LLC bought a new stake in IQVIA during the 4th quarter worth approximately $33,000. Avior Wealth Management LLC boosted its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. grew its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Finally, UMB Bank n.a. increased its holdings in shares of IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after purchasing an additional 99 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Down 0.7 %

Shares of NYSE IQV opened at $206.67 on Tuesday. The company has a market cap of $37.51 billion, a price-to-earnings ratio of 27.56, a PEG ratio of 2.25 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm’s fifty day moving average is $200.67 and its 200 day moving average is $219.27. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on IQV shares. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. TD Cowen cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Redburn Atlantic initiated coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Bank of America cut their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $252.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.